Limit this search to....

Hereditary Tyrosinemia: Pathogenesis, Screening and Management Softcover Repri Edition
Contributor(s): Tanguay, Robert M. (Editor)
ISBN: 3319857452     ISBN-13: 9783319857459
Publisher: Springer
OUR PRICE:   $189.99  
Product Type: Paperback - Other Formats
Published: August 2018
Qty:
Temporarily out of stock - Will ship within 2 to 5 weeks
Additional Information
BISAC Categories:
- Science | Life Sciences - Biochemistry
- Science | Life Sciences - Molecular Biology
Dewey: 572.6
Series: Advances in Experimental Medicine and Biology
Physical Information: 247 pages
 
Descriptions, Reviews, Etc.
Publisher Description:
Hereditary tyrosinemia type 1 (HT1), the most severe inborn error of the tyrosine degradation pathway, is due to a deficiency in fumarylacetoacetate hydrolase (FAH). The worldwide frequency of HT1 is one per 100,000 births, but some regions have a significantly higher incidence (1:1,800). The FAH defect results in the accumulation of toxic metabolites, mainly in the liver. If left untreated, HT1 is usually fatal before the age of two. HT1 patients develop several chronic complications including cirrhosis with a high risk of hepatocellular carcinoma (HCC) and neuropsychological impairment. Treatment comprises an inhibitor of the pathway, Nitisinone, a strict dietary treatment or liver transplantation. Early treatment is important to avoid HCC. The book includes the latest developments on the molecular basis of HT1, its pathology, screening and diagnosis and management of the disease written by leading scientists, geneticists, hepatologists and clinicians in the field.